$BCLI
Brainstorm Cell Therapeutics Inc Stock $bcli

$bcli Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000114420414048755 Filed on August 12, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$860.0K	$420.0K	$740.0K
YoY Change	218.52%	-43.24%	64.44%
% of Gross Profit
Research & Development	$1.572M	$877.0K	$742.0K
YoY Change	95.52%	18.19%	92.73%
% of Gross Profit
Depreciation & Amortization	$30.00K	$20.00K	$20.00K
YoY Change	0.0%	0.0%	-50.0%
% of Gross Profit
Operating Expenses	$2.428M	$1.294M	$1.485M
YoY Change	125.65%	-12.86%	78.27%
Operating Profit	-$2.430M	-$1.294M	-$1.500M
YoY Change	124.79%	-13.73%	80.94%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$10.00K	-$690.0K	-$20.00K
YoY Change	-200.0%	3350.0%
Pretax Income	-$2.420M	-$1.980M	-$1.500M
YoY Change	124.07%	32.0%	80.72%
Income Tax	$0.00	$0.00	$18.00K
% Of Pretax Income
Net Earnings	-$2.421M	-$1.984M	-$1.518M
YoY Change	123.75%	30.7%	82.89%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$159.6K	-$159.4K	-$149.5K
COMMON SHARES
Basic Shares Outstanding	227.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.57M	$11.33M	$2.540M
YoY Change	106.45%	346.06%	202.38%
Cash & Equivalents	$8.969M	$11.33M	$755.0K
Short-Term Investments	$1.600M		$1.780M
Other Short-Term Assets	$90.00K	$50.00K	$140.0K
YoY Change	50.0%	-64.29%	0.0%
Inventory
Prepaid Expenses	$88.00K	$48.00K	$135.0K
Receivables	$450.0K	$830.0K	$620.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.11M	$12.21M	$3.290M
YoY Change	95.82%	271.03%	135.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$270.0K	$302.0K	$263.0K
YoY Change	1.12%	14.83%	-12.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$20.00K	$20.00K	$240.0K
YoY Change	-92.59%	-91.67%	84.62%
Total Long-Term Assets	$293.0K	$317.0K	$504.0K
YoY Change	-45.74%	-37.1%	12.0%
TOTAL ASSETS
Total Short-Term Assets	$11.11M	$12.21M	$3.290M
Total Long-Term Assets	$293.0K	$317.0K	$504.0K
Total Assets	$11.40M	$12.52M	$3.794M
YoY Change	83.52%	230.1%	105.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.300M	$757.0K	$373.0K
YoY Change	191.48%	102.95%	-28.27%
Accrued Expenses	$820.0K	$755.0K	$606.0K
YoY Change	15.49%	24.59%	-23.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.400M	$1.782M	$1.200M
YoY Change	73.16%	48.5%	-17.24%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$100.0K	$140.0K	$240.0K
YoY Change	-65.52%	-41.67%	60.0%
Total Long-Term Liabilities	$104.0K	$142.0K	$240.0K
YoY Change	-64.14%	-40.83%	60.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.400M	$1.782M	$1.200M
Total Long-Term Liabilities	$104.0K	$142.0K	$240.0K
Total Liabilities	$2.499M	$1.924M	$1.439M
YoY Change	49.02%	33.7%	-10.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$58.92M
YoY Change
Common Stock	$67.82M	$67.10M	$52.46M
YoY Change	21.71%	27.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.901M	$10.60M	$2.360M
YoY Change
Total Liabilities & Shareholders Equity	$11.40M	$12.52M	$3.790M
YoY Change	83.52%	230.45%	104.86%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$2.421M	-$1.984M	-$1.518M
YoY Change	123.75%	30.7%	82.89%
Depreciation, Depletion And Amortization	$30.00K	$20.00K	$20.00K
YoY Change	0.0%	0.0%	-50.0%
Cash From Operating Activities	-$1.119M	-$970.0K	-$1.063M
YoY Change	56.94%	-8.75%	153.7%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$46.00K
YoY Change	-100.0%	-100.0%	411.11%
Acquisitions
YoY Change
Other Investing Activities	-$1.610M	$0.00	-$10.00K
YoY Change	-46.51%	-100.0%
Cash From Investing Activities	-$1.606M	-$2.000K	-$57.00K
YoY Change	-47.15%	-96.49%	533.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	-$104.0K	$9.658M	$0.00
YoY Change	-103.13%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$366.0K	$9.273M	$7.000K
YoY Change	-89.0%	132371.43%	-94.44%
NET CHANGE
Cash From Operating Activities	-$1.119M	-$970.0K	-$1.063M
Cash From Investing Activities	-$1.606M	-$2.000K	-$57.00K
Cash From Financing Activities	$366.0K	$9.273M	$7.000K
Net Change In Cash	-$2.359M	$8.301M	-$1.113M
YoY Change	453.76%	-845.82%	268.54%
FREE CASH FLOW
Cash From Operating Activities	-$1.119M	-$970.0K	-$1.063M
Capital Expenditures	$0.00	$0.00	$46.00K
Free Cash Flow	-$1.119M	-$970.0K	-$1.109M
YoY Change	50.4%	-12.53%	159.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q2	us-gaap	Assets Current AssetsCurrent	12207000	USD
CY2014Q2	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	831000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	529000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2497000	USD
CY2014Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	142000	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	655000	USD
CY2014Q2	us-gaap	Liabilities Liabilities	1924000	USD
CY2004Q2	bcli	Common Stock Transferred As Per Purchase Agreement CommonStockTransferredAsPerPurchaseAgreement	6880000	shares
CY2013	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	between 1-for-10 and 1-for-20
CY2014Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10500000	USD
CY2004Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
	bcli	Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus	0.05	pure
	bcli	Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus	0.03	pure
	bcli	Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus	P15Y
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11328000	USD
CY2014Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	48000	USD
CY2014Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	15000	USD
CY2014Q2	us-gaap	Long Term Investments LongTermInvestments	15000	USD
CY2013Q4	us-gaap	Long Term Investments LongTermInvestments	22000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	302000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	258000	USD
CY2014Q2	us-gaap	Assets Assets	12524000	USD
CY2013Q4	us-gaap	Assets Assets	4726000	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	757000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	228000	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	755000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	877000	USD
CY2014Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	270000	USD
CY2013Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	227000	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1782000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1332000	USD
CY2014Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	142000	USD
CY2013Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	655000	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	10000	USD
	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	1770000	USD
CY2013Q2	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	15000	USD
CY2014Q2	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	690000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2013Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2014Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2582000	USD
CY2014Q2	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	56502000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	10600000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12524000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	686000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	408000	USD
CY2013Q2	us-gaap	Share Based Compensation ShareBasedCompensation	385000	USD
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	176000	USD
CY2013Q2	invest	Investment Options Exercise Price InvestmentOptionsExercisePrice	0.15
CY2013Q2	bcli	Common Stock Purchased From Option Granted CommonStockPurchasedFromOptionGranted	460000	shares
CY2014Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	67092000	USD
CY2009	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1120000	shares
CY2011Q1	bcli	Amount Due To Investors AmountDueToInvestors	20000	USD
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	225472618	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	176263587	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	225472618	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	176263587	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1264000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1557000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	742000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	877000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1302000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	768000	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	743000	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	417000	USD
	us-gaap	Operating Expenses OperatingExpenses	2566000	USD
	us-gaap	Operating Expenses OperatingExpenses	2325000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	1485000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	1294000	USD
	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	16000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4095000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1500000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1984000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18000	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2600000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4095000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-1518000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-1984000	USD
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.02
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	52407000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	2739000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4726000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	181307151	shares
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.02
CY2013Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.01
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.01
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	151754312	shares
CY2013Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1063000	USD
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	152546703	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	186253752	shares
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	3982000	USD
CY2013	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	197000	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	674000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	298000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	USD
	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	215000	USD
CY2013	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	250000	USD
	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	9658000	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	30000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-4899000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity		USD
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity		USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	50000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	50000	USD
CY2013Q2	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	17000	USD
CY2014Q2	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	25000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	202000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	110000	USD
CY2013Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	74000	USD
CY2014Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	514000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	298000	USD
CY2013Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	311000	USD
CY2014Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	176000	USD
	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	-33000	USD
	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	-64000	USD
CY2013Q2	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	95000	USD
CY2014Q2	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	53000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	15000	USD
CY2013Q2	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	127000	USD
CY2014Q2	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	431000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	53000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-79000	USD
CY2013Q2	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	21000	USD
CY2014Q2	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-256000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1762000	USD
CY2013Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2014Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	691000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1733000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1361000	USD
CY2014Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-970000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	66000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	94000	USD
CY2013Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	46000	USD
CY2014Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-989000	USD
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	0	USD
CY2013Q2	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	8000	USD
	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	9000	USD
	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	-7000	USD
CY2013Q2	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	3000	USD
CY2013Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7000	USD
CY2014Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	215000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	257000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9273000	USD
CY2014Q2	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	2000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	914000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-87000	USD
CY2013Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-57000	USD
CY2014Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	250000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9658000	USD
CY2013Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9658000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	215000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	bcli	Noncash Financing Activities NoncashFinancingActivities	0	USD
CY2013Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7000	USD
CY2014Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9273000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-562000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	7825000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1113000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8301000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1317000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1868000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3027000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	755000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	BRAINSTORM CELL THERAPEUTICS INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001137883
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	BCLI
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	227355671	shares
	bcli	Stock Issued During Period Value Issued For Warrants Exchange StockIssuedDuringPeriodValueIssuedForWarrantsExchange	1633000	USD
	bcli	Adjustments To Additional Paid In Capital Warrant Redemption In Cash AdjustmentsToAdditionalPaidInCapitalWarrantRedemptionInCash	42000	USD
	us-gaap	Stock Issued1 StockIssued1	1633000	USD
CY2013Q2	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2014Q2	us-gaap	Stock Issued1 StockIssued1	1633000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	-42000	USD
CY2013Q2	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2014Q2	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	-42000	USD
	bcli	Noncash Financing Activities NoncashFinancingActivities	1675000	USD
CY2013Q2	bcli	Noncash Financing Activities NoncashFinancingActivities	0	USD
CY2014Q2	bcli	Noncash Financing Activities NoncashFinancingActivities	1675000	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	600000	USD
CY2013Q2	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2014Q2	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	600000	USD

Files In Submission

Name	View Source	Status
0001144204-14-048755-index-headers.html	Edgar Link	pending
0001144204-14-048755-index.html	Edgar Link	pending
0001144204-14-048755.txt	Edgar Link	pending
0001144204-14-048755-xbrl.zip	Edgar Link	pending
bcli-20140630.xml	Edgar Link	completed
bcli-20140630.xsd	Edgar Link	pending
bcli-20140630_cal.xml	Edgar Link	unprocessable
bcli-20140630_def.xml	Edgar Link	unprocessable
bcli-20140630_lab.xml	Edgar Link	unprocessable
bcli-20140630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v385077_10q.htm	Edgar Link	pending
v385077_ex10-1.htm	Edgar Link	pending
v385077_ex10-2.htm	Edgar Link	pending
v385077_ex10-3.htm	Edgar Link	pending
v385077_ex10-4.htm	Edgar Link	pending
v385077_ex31-1.htm	Edgar Link	pending
v385077_ex31-2.htm	Edgar Link	pending
v385077_ex32-1.htm	Edgar Link	pending
v385077_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCLI
Brainstorm Cell Therapeutics Inc Stock $bcli

2014 Q3 Form 10-Q Financial Statement

#000114420414048755 Filed on August 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI Brainstorm Cell Therapeutics Inc Stock $bcli

2014 Q3 Form 10-Q Financial Statement

#000114420414048755 Filed on August 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI
Brainstorm Cell Therapeutics Inc Stock $bcli